NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

糖尿病神經病變的全球市場 (2020-2027年)

Global Diabetic Neuropathy Market - 2020-2027

出版商 DataM Intelligence 商品編碼 968951
出版日期 內容資訊 英文 266 Pages
商品交期: 最快1-2個工作天內
價格
糖尿病神經病變的全球市場 (2020-2027年) Global Diabetic Neuropathy Market - 2020-2027
出版日期: 2020年09月30日內容資訊: 英文 266 Pages
簡介

全球糖尿病神經病變的市場規模在2020年∼2027年的預測期間內,預計將以5.9%的年複合成長率擴大。

除了提高對2型糖尿病的認識和診斷外,人口老齡化,肥胖增加和久坐的生活方式增加等因素將進一步推動DN市場上的銷售額。

本報告提供全球糖尿病神經病變 市場相關調查,提供市場概要,各市場區隔及地區別的市場分析與預測,競爭情形分析,並提供主要企業簡介等資訊。

目錄

第1章 全球糖尿病神經病變市場:調查手法·範圍

  • 調查手法
  • 調查範圍

第2章 全球糖尿病神經病變市場:趨勢

第3章 全球糖尿病神經病變市場:產業分析

  • 市場促進因素
    • 糖尿病的患病者·發病者的增加
    • 老年人口的的增加DN發生率的上升
    • 管道新治療方法的認證
  • 市場阻礙因素
    • DN市場以仿製藥為主導,這增加了進入新藥療法的障礙
  • 威脅和機會
  • 波特的五力分析

第4章 全球糖尿病神經病變市場:市場分析

  • 糖尿病神經病變市場:各類型
    • 末梢神經病變
    • 植物性神經障礙
    • 糖尿病性筋委縮小症
    • 局部性神經病變
  • 糖尿病神經病變市場:各治療類型
    • 藥物療法
    • 非藥物療法
    • 糖尿病神經病變市場:各流通管道

第5章 全球糖尿病神經病變市場:地區分析

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他南美
  • 其他地區

第6章 全球糖尿病神經病變市場:競爭情形

  • 市場佔有率分析
  • 合併和收購分析
  • 新產品的銷售

第7章 全球糖尿病神經病變市場:企業簡介

  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly
  • Endo Health Solutions
  • Glenmark Pharmaceuticals
  • Grunenthal
  • Janssen Pharmaceuticals
  • Johnson and Johnson
  • Lupin Limited
  • NeuroMetrix, Inc.
  • Novartis AG
  • Pfizer, Inc

第8章 全球糖尿病神經病變市場:附錄

目錄

Market Overview

The Global Diabetic Neuropathy Market is expected to grow at a CAGR of 5.9% during the forecasting period (2020-2027).

Diabetic Neuropathy (DN) refers to nerve fiber damage caused by diabetes. It is a common yet serious complication of diabetes.

Between 60% to 70% of people with diabetes develop some form of neuropathy. The highest rates of neuropathy are among people who have had the disease for over 25 years.

According to the International Diabetes Federation (IDF), the number of people with diabetes worldwide was estimated at 366 million in 2011 and is expected to rise to 522 million in 2030.

This dramatically increasing prevalence of diabetes, which is likely to double over the next 10 years, will greatly increase the patient pool for DN.

Thus, this represents a huge market opportunity for the global Diabetic Neuropathy market. In addition to growing awareness and diagnosis of type 2 diabetes, factors such as aging population, the rise in obesity, and the increasingly sedentary lifestyles will further drive the sales in the DN market.

However, the diabetic neuropathy market is largely dominated by generics, which raises the barrier to entry for novel drug therapies, thereby acting as a growth deterrent to the global Diabetic Neuropathy market.

Market Outlook

Currently, there are no approved disease-modifying therapies for different forms of diabetic neuropathy. An incomplete understanding of the pathophysiology of DN has made drug development challenges.

A number of potential novel candidates are currently being evaluated for the effective treatment of DN.

Diabetic neuropathy imposes a significant burden on the healthcare systems of developed economies.

Market Segmentation

Depending upon the part of a body where the nerve damage occurs, DN is classified into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy.

Peripheral Neuropathy, which affects the feet and hands, accounts for the largest share in the DN market. This is because peripheral neuropathy is the most common form of DN with 60-70% of diabetic patients having this type of neuropathy.

An estimated 15-18 million Americans suffer from peripheral neuropathy, representing over one-third of all neuropathies.

Insights, and Trends

Segmentation based on treatment type includes pharmacological approach and non-pharmacological management. Pharmacological approach is further sub-segmented into drug classes such as analgesic, antidepressant, and anticonvulsants.

Since pharmacotherapy is not entirely successful, non-pharmacological treatment options such as electrostimulation, Electromagnetic field treatment, low-intensity laser treatment are also considered.

Lastly, the market is classified based on the distribution channel into Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy.

Market Trends

Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

North America is the largest market for Diabetic Neuropathy owing to the highest prevalence of diabetes in the adult population, noted at 7.9%. The US itself represents a huge market opportunity as the US obesity epidemic will lead to an increased prevalence of type 2 diabetes, and consequently, an increased prevalence of DN.

The North America market for Diabetic Neuropathy was valued at USD X billion in 2017 and is expected to grow at a CAGR of X% over the forecast period.

Asia Pacific region is expected to be the fastest growing region. The prevalence of type 1 and type 2 diabetes has been rapidly increasing in developing countries due to dynamic and ongoing socioeconomic transition and the ensuing changes in lifestyle factors.

Out of the total people with diabetes across the globe, more than 60% live in Asia, with almost one-half in China and India combined.

Key company profiles

The report profiles the following companies in the Diabetic Neuropathy market Pfizer, Eli Lilly, Lupin Limited, Glenmark Pharmaceuticals, Astellas Pharma and so on.

The scope of The Report:

By Type

Peripheral Neuropathy

Autonomic Neuropathy

Proximal Neuropathy

Focal Neuropathy

By Treatment Type

Pharmacological Treatment

Non-Pharmacological Treatment

By Distribution Channel

Hospitals

Clinics

Retail Pharmacy

Online Pharmac

By Region

Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific).Europe (Germany, France, The UK, Italy, Spain, Rest of Europe).

North America (The USA, Canada, Mexico).

South America (Brazil, Argentina, Rest of South America).

Rest of the World.

Why purchase the report?

Visualize the composition of the Diabetic Neuropathy market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.

Identify commercial opportunities in Diabetic Neuropathy by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of the Diabetic Neuropathy market level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key Diabetic Neuropathy of all major market players

Target Audience

Equipment Suppliers/ Buyers

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Diabetic Neuropathy Market -Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Report

2. Global Diabetic Neuropathy Market - Trends

  • 2.1. Key Trends & Developments

3. Global Diabetic Neuropathy Market - Industry Analysis

  • 3.1. Market Drivers
    • 3.1.1. Increasing prevalence and diagnosis of diabetes
    • 3.1.2. Increasing DN incidence due to the growing elderly population
    • 3.1.3. Approval of novel therapies in the pipeline
  • 3.2. Market Restraints
    • 3.2.1. DN market is dominated by generics, which raises the barrier to entry for novel drug therapies
  • 3.3. Threats and Opportunities
  • 3.4. Porter's 5 Forces

4. Global Diabetic Neuropathy Market - Market Analysis

  • 4.1. Diabetic Neuropathy Market By Type
    • 4.1.1. Peripheral Neuropathy
    • 4.1.2. Autonomic Neuropathy
    • 4.1.3. Proximal Neuropathy
    • 4.1.4. Focal Neuropathy
  • 4.2. Diabetic Neuropathy Market- By Treatment Type
    • 4.2.1. Pharmacological Treatment
      • 4.2.1.1. Antidepressants
      • 4.2.1.1.1. Tricyclic Antidepressants (TCAs)
      • 4.2.1.1.1.1. Amitriptyline
      • 4.2.1.1.1.2. Nortriptyline
      • 4.2.1.1.1.3. Desipramine
      • 4.2.1.1.1.4. Imipramine
      • 4.2.1.1.2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
      • 4.2.1.1.2.1. Duloxetine
      • 4.2.1.1.2.2. Venlafaxine
      • 4.2.1.1.3. Serotonin Reuptake Inhibitors (SSRIs)
      • 4.2.1.1.3.1. Citalopram
      • 4.2.1.1.3.2. Paroxetine
      • 4.2.1.2. Anticonvulsants
      • 4.2.1.2.1. Calcium alpha-2-delta anticonvulsants
      • 4.2.1.2.1.1. Gabapentin
      • 4.2.1.2.1.2. Pregabalin
      • 4.2.1.2.2. Sodium channel anticonvulsants
      • 4.2.1.2.2.1. Carbamazepine
      • 4.2.1.2.2.2. Topiramate
      • 4.2.1.3. Analgesics
      • 4.2.1.3.1. Opioid Analgesics
      • 4.2.1.3.1.1. Morphine
      • 4.2.1.3.1.2. Oxycodone
      • 4.2.1.3.1.3. Tapentadol
      • 4.2.1.3.2. Topical Analgesics
      • 4.2.1.3.2.1. Capsaicin
      • 4.2.1.3.2.2. Lidocaine
    • 4.2.2. Non-Pharmacological Treatment
      • 4.2.2.1. Transcutaneous Electrical Nerve Stimulation (TENS)
      • 4.2.2.2. Frequency Pulsed Magnetic therapy
      • 4.2.2.3. Low-intensive laser therapy
      • 4.2.2.4. Monochromatic infrared light/ Monochromatic infrared energy (MIRE)
      • 4.2.2.5. Physiotherapy
      • 4.2.2.6. Acupuncture
    • 4.2.3. Diabetic Neuropathy Market- By Distribution Channel
      • 4.2.3.1. Hospitals
      • 4.2.3.2. Clinics
      • 4.2.3.3. Retail Pharmacy
      • 4.2.3.4. Online Pharmacy

5. Global Diabetic Neuropathy Market - Geographical Analysis

  • 5.1. North America
    • 5.1.1. The USA
    • 5.1.2. Canada
    • 5.1.3. Mexico
  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. The UK
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. Rest of Europe
  • 5.3. Asia Pacific
    • 5.3.1. China
    • 5.3.2. Japan
    • 5.3.3. India
    • 5.3.4. Australia
    • 5.3.5. Rest of Asia Pacific
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5. Rest of the World

6. Global Diabetic Neuropathy Market - Competitive Landscape

  • 6.1. Market Share Analysis
  • 6.2. Mergers and Acquisitions Analysis
  • 6.3. New Product Launches

7. Global Diabetic Neuropathy Market - Company Profiles*

  • 7.1. Astellas Pharma Inc.
  • 7.2. Boehringer Ingelheim GmbH
  • 7.3. Eli Lilly
  • 7.4. Endo Health Solutions
  • 7.5. Glenmark Pharmaceuticals
  • 7.6. Grunenthal
  • 7.7. Janssen Pharmaceuticals
  • 7.8. Johnson and Johnson
  • 7.9. Lupin Limited
  • 7.10. NeuroMetrix, Inc.
  • 7.11. Novartis AG
  • 7.12. Pfizer, Inc

8. Global Diabetic Neuropathy Market - Appendix

  • 8.1. Sources
  • 8.2. List of Tables
  • 8.3. Expert Panel Validation
  • 8.4. Disclaimer
  • 8.5. Contact Us
  • Note: Additional company profiles will be included on client request.